RMD: Sleep Health Partnerships And Acquisitions Will Support Long Term Upside

ResMed's updated analyst price target has shifted lower to $270.60 from $288.21, as analysts factor in revised fair value assumptions and a more conservative future P/E outlook, while maintaining steady expectations for revenue growth and profit margins.

Analyst Commentary

Recent Street research around ResMed has mixed implications for valuation and execution, with several firms trimming price targets while one major bank has started coverage with a positive stance.

Bullish Takeaways

Bullish analysts initiating coverage, including JPMorgan, see room for the stock to justify a higher valuation over time, even as near term price targets elsewhere are reset.
The constructive initiation suggests confidence that ResMed can execute on its growth plans and support earnings that align with a premium P/E multiple compared with what more cautious analysts are now using.
Supportive views highlight the company’s ability to maintain revenue growth and protect margins, which is central to any case for upside from the revised consensus target.
The mix of a bullish initiation alongside cuts from other firms gives investors a wider range of fair value views to compare, rather than a one way downgrade story.

Bearish Takeaways

Several bearish analysts have reduced their price targets, including cuts of US$5, US$12, US$29 and US$45, signalling more cautious assumptions on what investors should be willing to pay for ResMed’s earnings.
The target changes point to a more conservative future P/E outlook, with some analysts less comfortable assigning higher multiples without clearer evidence on execution and growth durability.
Lowered targets suggest concerns that previous fair value estimates may have been too optimistic, and that expectations for operational delivery and margin resilience should be tempered.
The clustering of target cuts over a relatively short period highlights a shift toward more risk aware positioning, which can cap near term valuation even if the underlying business story remains intact.

What's in the News

ResMed completed its US$340 million acquisition of Noctrix Health, adding the FDA De Novo authorized Nidra device for moderate to severe Restless Legs Syndrome to its sleep health portfolio and planning to integrate the technology into its connected devices and digital health offerings. Source: company and Noctrix announcements
The Noctrix deal includes plans to invest in research and development, sales, and marketing. Noctrix will operate as a wholly owned subsidiary that leverages existing physician and home medical equipment provider relationships to expand patient access and support ResMed’s 2030 growth strategy. Source: Noctrix acquisition disclosures
ResMed and Oura agreed a partnership that connects Oura Ring Gen3 and Ring 4 sleep data with ResMed’s sleep education, assessments, and links to independent healthcare providers. The partnership aims to turn wellness insights into clinical evaluations for conditions such as obstructive sleep apnea. Source: ResMed and Oura client announcement, May 19, 2026
ResMed announced that long time Chief Financial Officer Brett Sandercock will retire. Aaron Bloomer, formerly CFO of Exact Sciences, has been appointed as his successor effective May 4, 2026, while Sandercock remains an advisor to the CEO through the end of 2027. Source: company executive changes filing
From January 1 to March 31, 2026, ResMed repurchased 673,418 shares for US$175 million, completing a cumulative 11,110,066 share buyback for US$1,363.36 million under its program first announced in 2014. Source: company buyback update

Valuation Changes

Fair Value: The consensus fair value estimate has fallen modestly from $288.21 to $270.60, reflecting slightly more cautious assumptions on what investors may pay for the stock.
Discount Rate: The discount rate has eased from 7.85% to 7.50%, a small change that marginally increases the present value of future cash flows used in some analyst models.
Revenue Growth: The long term revenue growth assumption has risen slightly from 7.60% to 7.67%, indicating a small upward adjustment in expected top line expansion.
Net Profit Margin: The projected net profit margin has edged down from 28.82% to 28.67%, suggesting a minor reduction in expected profitability levels.
Future P/E: The future P/E multiple has fallen from 26.49x to 23.93x, pointing to a more conservative view on how much investors may be willing to pay for ResMed’s earnings.

4 views

Key Takeaways

Strategic acquisitions, innovation, and digital health adoption are broadening market reach, deepening customer retention, and driving resilient revenue and margin growth.
Operational efficiencies and increased awareness in sleep health strengthen competitive advantages, fueling long-term earnings expansion and greater profitability.
Competitive, regulatory, and market shifts threaten ResMed's pricing power, market share, and profitability, especially as its hardware-focused model faces digital disruption and rising compliance costs.

Catalysts

About ResMed

Develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets.What are the underlying business or industry changes driving this perspective?

Strategic investments in expanding the diagnosis and treatment funnel-including acquisitions like VirtuOx, Ectosense, and Somnoware-are improving patient flow from screening to therapy, positioning ResMed to capture a larger share of the substantial underpenetrated global sleep apnea and respiratory market, supporting long-term revenue growth.
Increased global awareness of sleep health issues, amplified by direct-to-consumer marketing campaigns and education programs for primary care physicians, is driving higher diagnosis and treatment rates, translating to elevated demand for ResMed's products and sustained top-line revenue growth.
Acceleration in adoption of home-based, cloud-connected therapy solutions and digital health platforms (including software like Brightree and AirView) enhances recurring high-margin revenue streams and increases both user retention and net profit margins over time.
Ongoing innovation in product development-including new releases of CPAP devices, mask interfaces, and integration of AI-driven features-strengthens ResMed's competitive differentiation and supports premium pricing power, driving both revenue and margin expansion.
Optimization initiatives in procurement, manufacturing, and logistics-along with the build-out of the U.S. manufacturing footprint-are structurally improving gross margins, which, when combined with operating leverage from global scale, are expected to boost overall earnings and free cash flow.

ResMed Future Earnings and Revenue Growth

Assumptions

How have these above catalysts been quantified?

Analysts are assuming ResMed's revenue will grow by 7.7% annually over the next 3 years.
Analysts assume that profit margins will increase from 27.4% today to 28.7% in 3 years time.
Analysts expect earnings to reach $2.0 billion (and earnings per share of $13.91) by about June 2029, up from $1.5 billion today. The analysts are largely in agreement about this estimate.
In order for the above numbers to justify the price target of the analysts, the company would need to trade at a PE ratio of 23.9x on those 2029 earnings, up from 18.5x today. This future PE is lower than the current PE for the AU Medical Equipment industry at 24.3x.
Analysts expect the number of shares outstanding to decline by 0.93% per year for the next 3 years.
To value all of this in today's terms, we will use a discount rate of 7.5%, as per the Simply Wall St company report.

Risks

What could happen that would invalidate this narrative?

The potential resumption or tightening of CMS competitive bidding programs in the US could pressure pricing and reimbursement rates for ResMed's core devices, leading to reduced revenue growth and compressed net margins.
Intensifying competition in the sleep apnea and respiratory market-including from alternative therapies such as GLP-1 drugs and hypoglossal nerve stimulators-may slow device adoption and erode ResMed's market share, negatively impacting topline revenue and margins.
Heavy dependence on positive secular trends (aging population, home-based care, and sleep disorder prevalence) exposes ResMed to risk if healthcare cost containment or stricter reimbursement policies emerge globally, which could limit growth and pressure earnings.
The accelerating transition toward digital and preventative health, as well as commoditization of respiratory medical equipment, may lower average selling prices and challenge ResMed's hardware-centric business model, impacting net margin expansion and longer-term profitability.
Rising regulatory and compliance demands-especially related to data privacy, cybersecurity, and evolving healthcare software oversight-could increase R&D and SG&A costs, pose legal risks, and potentially delay new product launches, putting pressure on future earnings and operating leverage.

Valuation

How have all the factors above been brought together to estimate a fair value?

The analysts have a consensus price target of $270.6 for ResMed based on their expectations of its future earnings growth, profit margins and other risk factors.
However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $340.0, and the most bearish reporting a price target of just $180.0.
In order for you to agree with the analysts, you'd need to believe that by 2029, revenues will be $6.9 billion, earnings will come to $2.0 billion, and it would be trading on a PE ratio of 23.9x, assuming you use a discount rate of 7.5%.
Given the current share price of $194.32, the analyst price target of $270.6 is 28.2% higher.
We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.

Have other thoughts on ResMed?

Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.

Create Narrative

How well do narratives help inform your perspective?

Disclaimer

AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.

Analyst Commentary Highlights Margin Optimism as ResMed Faces Market Headwinds and Patent Challenge

RMD: Sleep Health Partnerships And Acquisitions Will Support Long Term Upside